Home / Market News / $ADAG
benzinga Corporate Catalyst Impact 65/100 ● neutral

Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9

Sep 10, 2026, 11:49 AM UTC · Primary ticker $ADAG

Chardan Capital has initiated coverage on Adagene with a 'Buy' rating and set a price target of $9. This analyst coverage can provide increased visibility and potentially positive sentiment for the stock.

Chardan Capital's initiation of coverage on Adagene with a 'Buy' rating and a $9 price target is a positive development for the company. Analyst coverage often brings increased investor awareness and can lead to higher trading volumes and potentially a re-evaluation of the stock's valuation. This is particularly significant for smaller biotechnology companies like Adagene, as it can attract new institutional and retail investors. In the short term, this news could lead to an upward movement in ADAG's stock price due to increased buying interest. Long-term implications depend on Adagene's clinical pipeline progress and financial performance, but positive analyst sentiment provides a good foundation. A key opportunity for traders is to capitalize on the potential immediate price appreciation following the news.

$ADAG positive New analyst coverage with positive rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.